Tomasz Olesinski

Head of Surgical Department

Maria Sklodowska-Curie National Research Institute of Oncology

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Tomasz Olesinski is the Head of the Surgical Department at the Maria Sklodowska-Curie National Research Institute of Oncology in Poland. His research focuses on oncology, specifically related to gastric and gastroesophageal junction cancers, investigating predictive factors for treatment response, surgical quality, and long-term patient outcomes. Recent publications highlight the efficacy of treatment regimens and the molecular mechanisms involved in cancer cell vulnerabilities.

Articles (10)

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Magdalena Cybulska-Lubak

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tomasz Olesinski

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Interleukin-6 as a Predictive Factor of Pathological Response to FLOT Regimen Systemic Treatment in Locally Advanced Gastroesophageal Junction or Gastric Cancer Patients

Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial.

The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells.

The influence of surgery quality on the longtime results of gastric cancer combination therapy

Long-term observation of gastric patients with positive immunocytochemistry of peritoneal washing.

The surgical treatment of rectal cancer in Poland. The findings of a multi-center observational study by the Polish Society of Surgical Oncology (PSSO-01)

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.

Does epidural analgesia modify the risk of complications after gastrectomy?

Long noncoding RNA CCAT1 rs67085638 SNP contribution to the progression of gastric cancer in a Polish population.

Long-term results of randomized studies on the use of a gentamicin-collagen sponge in rectal cancer – depending on the length of time between the completion of radiotherapy and the surgery

Collaborators (1)

Magdalena Cybulska-Lubak

Make your next move.